Browse NLRX1

Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion outer membrane
Domain PF13516 Leucine Rich repeat
Function

Participates in antiviral signaling. Acts as a negative regulator of MAVS-mediated antiviral responses, through the inhibition of the virus-induced RLH (RIG-like helicase)-MAVS interaction (PubMed:18200010). Instead, promotes autophagy by interacting with TUFM and subsequently recruiting the autophagy-related proteins ATG5 and ATG12 (PubMed:22749352). Regulates also MAVS-dependent NLRP3 inflammasome activation to attenuate apoptosis (PubMed:27393910). Has no inhibitory function on NF-kappa-B signaling pathway, but enhances NF-kappa-B and JUN N-terminal kinase dependent signaling through the production of reactive oxygen species (PubMed:18219313).

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002831 regulation of response to biotic stimulus
GO:0002832 negative regulation of response to biotic stimulus
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0009615 response to virus
GO:0030522 intracellular receptor signaling pathway
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032606 type I interferon production
GO:0032608 interferon-beta production
GO:0032635 interleukin-6 production
GO:0032648 regulation of interferon-beta production
GO:0032675 regulation of interleukin-6 production
GO:0032688 negative regulation of interferon-beta production
GO:0032715 negative regulation of interleukin-6 production
GO:0039528 cytoplasmic pattern recognition receptor signaling pathway in response to virus
GO:0039529 RIG-I signaling pathway
GO:0039531 regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway
GO:0039532 negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway
GO:0039535 regulation of RIG-I signaling pathway
GO:0039536 negative regulation of RIG-I signaling pathway
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045824 negative regulation of innate immune response
GO:0048525 negative regulation of viral process
GO:0050687 negative regulation of defense response to virus
GO:0050688 regulation of defense response to virus
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050792 regulation of viral process
GO:0051607 defense response to virus
GO:0098542 defense response to other organism
GO:0098586 cellular response to virus
GO:1902532 negative regulation of intracellular signal transduction
Molecular Function -
Cellular Component GO:0005741 mitochondrial outer membrane
GO:0019867 outer membrane
GO:0031968 organelle outer membrane
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NLRX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NLRX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NLRX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7110.0473
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0610.964
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.2850.147
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.140.717
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1380.938
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1470.949
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1790.546
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0870.935
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5140.675
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1540.887
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3490.822
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2460.0024
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NLRX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NLRX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NLRX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNLRX1
NameNLR family member X1
Aliases NOD9; CLR11.3; nucleotide-binding oligomerization domain, leucine rich repeat containing X1; NOD-like recept ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NLRX1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.